I agree that this site is using cookies. You can find further informations here.
X
Li, Chi‐Chung
343  results:
Search for persons X
?
1

Population pharmacokinetics and CD20 binding dynamics for m..:

Bender, Brendan ; Li, Chi‐Chung ; Marchand, Mathilde...
Clinical and Translational Science.  17 (2024)  6 - p. , 2024
Link: https://doi.org/10.1111/..
 
?
2

Considerations for Industry—Preparing for the FDA Model‐Inf..:

Galluppi, Gerald R. ; Ahamadi, Malidi ; Bhattacharya, Souvik...
Clinical Pharmacology & Therapeutics.  116 (2024)  2 - p. 282-288 , 2024
Link: https://doi.org/10.1002/..
 
?
3

Pharmacologic characterization of atogepant: A potent and s..:

Moore, Eric ; Bell, Ian M ; Fraley, Mark E...
Cephalalgia.  44 (2024)  1 - p. , 2024
Link: https://doi.org/10.1177/..
 
?
4

Assessment of CYP3A‐mediated drug interaction via cytokine ..:

Chen, Yuan ; Ma, Fang ; Jones, Nicholas...
CPT: Pharmacometrics & Systems Pharmacology.  13 (2023)  2 - p. 234-246 , 2023
Link: https://doi.org/10.1002/..
 
?
5

Systems‐based digital twins to help characterize clinical d..:

Susilo, Monica E. ; Li, Chi‐Chung ; Gadkar, Kapil...
Clinical and Translational Science.  16 (2023)  7 - p. 1134-1148 , 2023
Link: https://doi.org/10.1111/..
 
?
6

Mosunetuzumab monotherapy is active and tolerable in patien..:

Bartlett, Nancy L. ; Assouline, Sarit ; Giri, Pratyush...
Blood Advances.  7 (2023)  17 - p. 4926-4935 , 2023
Link: https://doi.org/10.1182/..
 
?
7

Oral Abstract: IBCL-249 Mosunetuzumab Monotherapy Is an Eff..:

Budde, Elizabeth L ; Sehn, Laurie H ; Matasar, Matthew...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S117 , 2022
Link: https://doi.org/10.1016/..
 
?
8

IBCL-249 Mosunetuzumab Monotherapy Is an Effective and Well..:

Budde, Elizabeth L ; Sehn, Laurie H ; Matasar, Matthew...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S387 , 2022
Link: https://doi.org/10.1016/..
 
?
9

Poster: IBCL-249 Mosunetuzumab Monotherapy Is an Effective ..:

Budde, Elizabeth L ; Sehn, Laurie H ; Matasar, Matthew...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S173 , 2022
Link: https://doi.org/10.1016/..
 
?
10

Poster: IBCL-373: Updated Experience from Mosunetuzumab in ..:

Assouline, Sarit ; Kim, Won Seog ; Sehn, Laurie H....
Clinical Lymphoma Myeloma and Leukemia.  21 (2021)  - p. S245 , 2021
Link: https://doi.org/10.1016/..
 
?
11

Industrial Perspective on the Benefits Realized From the FD..:

Galluppi, Gerald R. ; Brar, Satjit ; Caro, Luzelena...
Clinical Pharmacology & Therapeutics.  110 (2021)  5 - p. 1172-1175 , 2021
Link: https://doi.org/10.1002/..
 
?
12

IBCL-373: Updated Experience from Mosunetuzumab in Multiple..:

Assouline, Sarit ; Kim, Won Seog ; Sehn, Laurie H....
Clinical Lymphoma Myeloma and Leukemia.  21 (2021)  - p. S406-S407 , 2021
Link: https://doi.org/10.1016/..
 
?
13

Ubrogepant Is Not Associated With Clinically Meaningful Ele..:

Ankrom, Wendy ; Bondiskey, Phung ; Li, Chi‐Chung...
Clinical and Translational Science.  13 (2020)  3 - p. 462-472 , 2020
Link: https://doi.org/10.1111/..
 
?
14

Making Better Dose Decisions: Using Exposure‐Response Model..:

Li, Chi‐Chung ; Voss, Tiffini ; Kowalski, Ken...
Clinical and Translational Science.  13 (2020)  3 - p. 482-490 , 2020
Link: https://doi.org/10.1111/..
 
?
15

Tumor Time‐Course Predicts Overall Survival in Non‐Small Ce..:

Netterberg, Ida ; Bruno, René ; Chen, Ya‐Chi...
CPT: Pharmacometrics & Systems Pharmacology.  9 (2020)  2 - p. 115-123 , 2020
Link: https://doi.org/10.1002/..
 
1-15